10Nov

Invasive Aspergillosis Screening in COVID-19 & Critical Care Patients

IMMY sõna Aspergillus Galactomannan Lateral Flow Assay recommended by the European Confederation of Medical Microbiology (ECMM) as a screening device in ventilated patients.

 

With the emergence of COVID-19, the disease caused by the SARS-CoV-2 virus, there has been a marked increase in patients being admitted into Intensive Care Units (ICU) and particularly those requiring invasive ventilation. In light of this, new guidance has been provided by the European Confederation of Medical Microbiology (ECMM) for the diagnosis and management of patients with acute respiratory distress syndrome (ARDS) and/or ICU treatment under mechanical ventilation due to suspected pneumonia.

The ECMM specifically recommends the use of IMMY’s Aspergillus GM LFA both as part of the initial microbiological diagnostic pathway in all ICU and/or ARDS ventilation patients and also as part of a continual, tri-weekly screening program for SARS-CoV-2 and Influenza A/B positive patients.

 

Available from Alpha Laboratories, the Aspergillus GM LFA is an immunochromatographic test system for the qualitative detection of Aspergillus Galactomannan in serum and bronchoalveolar lavage (BAL) samples, providing a simple, rapid diagnosis of invasive aspergillosis, an opportunistic fungal infection caused by species of the Aspergillus genus.

 

The Aspergillus GM LFA works synergistically with other procedures such as microbiological culture, biopsy histological examination and radiographic evidence, combining to aid in the diagnosis of aspergillosis. It is easy to use, and provides high sensitivity, specificity and a rapid 30-minute test time, eliminating the need for batch testing and speeding up your results.

 

The sõna LFA Cube Reader simplifies the assessment of the intensity of the appearing lines, and is intended to be used as an aid in the interpretation of results of the Aspergillus GM LFA.

 

Please visit www.alphalabs.co.uk/af2003-r for further information on the starter pack, or contact Alpha Laboratories on 0800 38 77 32 or email marketing@alphalabs.co.uk

Related

Cytox awarded new Innovate UK funding for Alzheimer’s disease testing

8 March 2018: Oxford & Manchester, UK. Cytox, an emerging precision medicine leader providing geneti...

Read More >

OGT launches enhanced SureSeq™ Interpret NGS analysis software

Powerful, flexible and easy-to-use analysis solution gets the most out of NGS data

Read More >

£1M funding for the development of a quantitative lateral flow Smartphone Reader

Abingdon Health announces £1M Innovate UK funding for the development of a fully quantitative latera...

Read More >

Helping You Stay Comfortable and COVID Secure

New Range of CE Certified Face Visors and Type II Masks with Introductory 10% Savings

Read More >

BBI Solutions broadens antibody portfolio and strengthens reagent technical support capabilities with acquisition of Maine Biotechnology Services

BBI Solutions (BBI) has announced the addition of over 80 new antibodies to its growing product port...

Read More >

UK lateral flow rapid test manufacturer Abingdon Health confirms expansion

Following a successful 2019, Abingdon Health is expanding its York-based facility, giving the compan...

Read More >